RCKT (Rocket Pharmaceuticals) E10: $-3.57 (As of Mar. 2026)


RCKT Rocket Pharmaceuticals Inc RCKT
30 GF Score
Price $3.84
! 3 Warning Signs
View Full Analysis

What is Rocket Pharmaceuticals E10?

Rocket Pharmaceuticals RCKT +9.25% 30 E10 is $-3.57 as of Mar. 2026. GuruFocus rates RCKT with a GF Score™ of 30/100. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Rocket Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2026 was $-0.420. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-3.57 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-07-04), Rocket Pharmaceuticals's current stock price is $3.84. Rocket Pharmaceuticals's E10 for the quarter that ended in Mar. 2026 was $-3.57. Rocket Pharmaceuticals's Shiller PE Ratio of today is .


Rocket Pharmaceuticals  (NAS:RCKT) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Rocket Pharmaceuticals E10 Related Terms


Rocket Pharmaceuticals E10 Historical Data

* Premium members only.

The historical data trend for Rocket Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rocket Pharmaceuticals E10 Chart

Rocket Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -5.05 -4.81 -3.66

Rocket Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.82 -4.84 -3.56 -3.66 -3.57

RCKT vs TENX, DMAC, AVIR: E10 Comparison

For the Biotechnology subindustry, Rocket Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rocket Pharmaceuticals Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rocket Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Rocket Pharmaceuticals's Shiller PE Ratio falls into.


RCKT
30GF Score
Rocket Pharmaceuticals Inc RCKT
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rocket Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Rocket Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.42/330.2130*330.2130
=-0.420

Current CPI (Mar. 2026) = 330.2130.

Rocket Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201606 -1.320 241.018 -1.809
201609 -1.640 241.428 -2.243
201612 -1.930 241.432 -2.640
201703 -0.390 243.801 -0.528
201706 -0.490 244.955 -0.661
201709 -0.990 246.819 -1.324
201712 -2.460 246.524 -3.295
201803 -0.420 249.554 -0.556
201806 -0.400 251.989 -0.524
201809 -0.400 252.439 -0.523
201812 -0.670 251.233 -0.881
201903 -0.430 254.202 -0.559
201906 -0.380 256.143 -0.490
201909 -0.380 256.759 -0.489
201912 -0.390 256.974 -0.501
202003 -0.450 258.115 -0.576
202006 -0.450 257.797 -0.576
202009 -0.530 260.280 -0.672
202012 -1.090 260.474 -1.382
202103 -0.650 264.877 -0.810
202106 -0.550 271.696 -0.668
202109 -0.790 274.310 -0.951
202112 -0.690 278.802 -0.817
202203 -0.670 287.504 -0.770
202206 -0.830 296.311 -0.925
202209 -0.870 296.808 -0.968
202212 -0.890 296.797 -0.990
202303 -0.730 301.836 -0.799
202306 -0.820 305.109 -0.887
202309 -0.750 307.789 -0.805
202312 -0.640 306.746 -0.689
202403 -0.660 312.332 -0.698
202406 -0.740 314.175 -0.778
202409 -0.710 315.301 -0.744
202412 -0.620 315.605 -0.649
202503 -0.560 319.799 -0.578
202506 -0.620 322.561 -0.635
202509 -0.450 324.800 -0.457
202512 -0.380 324.054 -0.387
202603 -0.420 330.213 -0.420

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $-3.57 mean?
Rocket Pharmaceuticals (RCKT) has a E10 of $-3.57 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Rocket Pharmaceuticals and its competitors.
Is Rocket Pharmaceuticals' E10 too high?
Rocket Pharmaceuticals' current E10 is $-3.57. Overall, Rocket Pharmaceuticals has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Rocket Pharmaceuticals' E10 compare to TENX and DMAC?
Rocket Pharmaceuticals' E10 of $-3.57 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Rocket Pharmaceuticals and its competitors. Rocket Pharmaceuticals's current E10 is $-3.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rocket Pharmaceuticals stock overvalued right now?
Rocket Pharmaceuticals (RCKT) has a current E10 of $-3.57. The current E10 is $-3.57. Rocket Pharmaceuticals' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Rocket Pharmaceuticals (RCKT), the current E10 is $-3.57 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rocket Pharmaceuticals Business Description

Other Exchanges 9IP1:Germany
Address 9 Cedarbrook Drive, Cranbury, NJ, USA, 08512
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
30GF Score

Get the complete analysis for RCKT

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.84
Price